JP2006505628A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006505628A5 JP2006505628A5 JP2005506111A JP2005506111A JP2006505628A5 JP 2006505628 A5 JP2006505628 A5 JP 2006505628A5 JP 2005506111 A JP2005506111 A JP 2005506111A JP 2005506111 A JP2005506111 A JP 2005506111A JP 2006505628 A5 JP2006505628 A5 JP 2006505628A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- composition according
- hsf
- protein
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 claims 57
- 239000012528 membrane Substances 0.000 claims 24
- 238000002360 preparation method Methods 0.000 claims 24
- 101700056002 FETHP Proteins 0.000 claims 21
- 101710023137 HSP90B1 Proteins 0.000 claims 20
- 102000010912 Transferrin-Binding Proteins Human genes 0.000 claims 20
- 230000000890 antigenic Effects 0.000 claims 16
- STCOOQWBFONSKY-UHFFFAOYSA-N Tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims 14
- 230000001580 bacterial Effects 0.000 claims 10
- 241000894006 Bacteria Species 0.000 claims 8
- 241000588653 Neisseria Species 0.000 claims 7
- 241000588650 Neisseria meningitidis Species 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 6
- 229940047650 Haemophilus influenzae Drugs 0.000 claims 4
- 241000606768 Haemophilus influenzae Species 0.000 claims 4
- 102000018358 Immunoglobulins Human genes 0.000 claims 4
- 108060003951 Immunoglobulins Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 150000004676 glycans Polymers 0.000 claims 4
- 239000000546 pharmaceutic aid Substances 0.000 claims 4
- 229920001282 polysaccharide Polymers 0.000 claims 4
- 239000005017 polysaccharide Substances 0.000 claims 4
- 150000004804 polysaccharides Polymers 0.000 claims 4
- 229960005486 vaccines Drugs 0.000 claims 4
- 206010060945 Bacterial infection Diseases 0.000 claims 3
- 101710019325 GDI2185 Proteins 0.000 claims 3
- 241000588655 Moraxella catarrhalis Species 0.000 claims 3
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 claims 3
- 101700036978 OMP Proteins 0.000 claims 3
- 101700064522 eaeA Proteins 0.000 claims 3
- 230000036039 immunity Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920001542 oligosaccharide Polymers 0.000 claims 3
- 150000002482 oligosaccharides Polymers 0.000 claims 3
- 238000011144 upstream manufacturing Methods 0.000 claims 3
- 101710008242 CMAS Proteins 0.000 claims 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000000240 adjuvant Effects 0.000 claims 2
- 230000000875 corresponding Effects 0.000 claims 2
- 102000037240 fusion proteins Human genes 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 108060004459 lpxM Proteins 0.000 claims 2
- 101700073655 oatWY Proteins 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 101700024616 siaA Proteins 0.000 claims 2
- 241000228212 Aspergillus Species 0.000 claims 1
- 208000002352 Blister Diseases 0.000 claims 1
- 101710035148 CTPsyn Proteins 0.000 claims 1
- 101700016165 CTRC Proteins 0.000 claims 1
- 206010061190 Haemophilus infection Diseases 0.000 claims 1
- 206010062204 Moraxella infection Diseases 0.000 claims 1
- 229940052778 Neisseria meningitidis Drugs 0.000 claims 1
- 241001174901 Neisseria meningitidis alpha275 Species 0.000 claims 1
- 241000947238 Neisseria meningitidis serogroup C Species 0.000 claims 1
- 241001573069 Neisseria meningitidis serogroup Y Species 0.000 claims 1
- 229940076185 Staphylococcus aureus Drugs 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 229940037645 Staphylococcus epidermidis Drugs 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- 229940031000 Streptococcus pneumoniae Drugs 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims 1
- 101700018751 Syna Proteins 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 230000001268 conjugating Effects 0.000 claims 1
- 101700063084 crtC Proteins 0.000 claims 1
- 101700065061 ctrA Proteins 0.000 claims 1
- 101700034812 ctrB Proteins 0.000 claims 1
- 101700032880 ctrD Proteins 0.000 claims 1
- 230000004665 defense response Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 229920000023 polynucleotide Polymers 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000001681 protective Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000002194 synthesizing Effects 0.000 claims 1
Claims (68)
- 同一の、または異なるグラム陰性細菌に由来する、単離されたトランスフェリン結合タンパク質(Tbp)またはその抗原性断片、および単離されたHsf様タンパク質またはその抗原性断片を含んでなる免疫原性組成物。
- トランスフェリン結合タンパク質またはその断片、およびHsf様タンパク質またはその断片がナイセリア属細菌(Neisseria)に由来する、請求項1に記載の免疫原性組成物。
- トランスフェリン結合タンパク質またはその断片が髄膜炎菌(N. meningitidis)に由来する、請求項1または2に記載の免疫原性組成物。
- Hsf様タンパク質またはその断片が髄膜炎菌に由来する、請求項1〜3のいずれか1つに記載の免疫原性組成物。
- トランスフェリン結合タンパク質またはその断片が髄膜炎菌血清群Bに由来する、請求項1〜4のいずれか1つに記載の免疫原性組成物。
- Hsf様タンパク質またはその断片が髄膜炎菌血清群Bに由来する、請求項1〜5のいずれか1つに記載の免疫原性組成物。
- トランスフェリン結合タンパク質またはその断片が淋菌(N. gonorrhoeae)に由来する、請求項1〜6のいずれか1つに記載の免疫原性組成物。
- Hsf様タンパク質またはその抗原性断片が淋菌に由来する、請求項1〜7のいずれか1つに記載の免疫原性組成物。
- トランスフェリン結合タンパク質またはその抗原性断片がモラクセラ・カタラーリス(Moraxella catarrhalis)に由来する、請求項1〜8のいずれか1つに記載の免疫原性組成物。
- Hsf様タンパク質またはその抗原性断片がモラクセラ・カタラーリスに由来する、請求項1〜9のいずれか1つに記載の免疫原性組成物。
- トランスフェリン結合タンパク質またはその抗原性断片がインフルエンザ菌(Haemophilus influenzae)に由来する、請求項1〜10のいずれか1つに記載の免疫原性組成物。
- Hsf様タンパク質またはその抗原性断片がインフルエンザ菌に由来する、請求項1〜11のいずれか1つに記載の免疫原性組成物。
- トランスフェリン結合タンパク質がTbpAまたはその抗原性断片である、請求項1〜12のいずれか1つに記載の免疫原性組成物。
- 高分子量型TbpA、または低分子量型TbpA、または高分子量型TbpAおよび低分子量型TbpAの両方を含んでなる、請求項13に記載の免疫原性組成物。
- Hsf様タンパク質がHsfまたはその抗原性断片である、請求項1〜14のいずれか1つに記載の免疫原性組成物。
- ナイセリア属細菌、モラクセラ・カタラーリスまたはインフルエンザ菌感染に対する感染防御応答を生じることができるTbpおよび/またはHsf様タンパク質の抗原性断片を含んでなる、請求項1〜15のいずれか1つに記載の免疫原性組成物。
- TbpAおよび/またはHsfの抗原性断片を含んでなる、請求項16に記載の免疫原性組成物。
- TbpおよびHsf様タンパク質またはそれらの抗原性断片からなる融合タンパク質を含んでなる、請求項1〜17のいずれか1つに記載の免疫原性組成物。
- TbpAおよびHsfまたはナイセリア属細菌に対する感染防御応答を生じることができるそれらの抗原性断片からなる融合タンパク質を含んでなる、請求項18に記載の免疫原性組成物。
- トランスフェリン結合タンパク質およびHsf様タンパク質の発現が、非改変グラム陰性細菌において自然に生じるよりも、少なくとも1.5倍高い、グラム陰性細菌に由来する外膜小胞調製物を含んでなる、分離された免疫原性組成物。
- 鉄制限条件下で増殖させることによってトランスフェリン結合タンパク質の発現がアップレギュレートされた、請求項20に記載の免疫原性組成物。
- 外膜小胞調製物の少なくとも一部がナイセリア属細菌に由来する、請求項20または21に記載の免疫原性組成物。
- 外膜小胞調製物の少なくとも一部が髄膜炎菌に由来する、請求項20〜22のいずれか1つに記載の免疫原性組成物。
- 外膜小胞調製物の少なくとも一部が髄膜炎菌血清群Bに由来する、請求項20〜23のいずれか1つに記載の免疫原性組成物。
- 外膜小胞調製物の少なくとも一部が淋菌に由来する、請求項20〜22のいずれか1つに記載の免疫原性組成物。
- 外膜小胞調製物の由来する宿主細胞が、LgtBおよびLgtEのうち1つ以上、好ましくは前者、の発現をダウンレギュレートするように遺伝子操作されている、請求項20〜25のいずれか1つに記載の免疫原性組成物。
- 外膜小胞調製物の由来する宿主細胞が、莢膜多糖を合成することができず、しかも好ましくは、siaD、ctrA、ctrB、ctrC、ctrD、synA(synXおよびsiaAに相当)、synB(siaBに相当)およびsynC(siaCに相当)のうち1つ以上、もっとも好ましくはsiaD、の発現をダウンレギュレートし、好ましくはそれらを欠失するように、遺伝子操作されている、請求項20〜26のいずれか1つに記載の免疫原性組成物。
- 外膜小胞調製物の由来する宿主細胞が、OpC、OpAおよびPorAのうち1つ以上、好ましくはPorA、の発現をダウンレギュレートし、好ましくはそれらを欠失するように、遺伝子操作されている、請求項20〜27のいずれか1つに記載の免疫原性組成物。
- 外膜小胞調製物の由来する宿主細胞が、FrpBの発現をダウンレギュレートし、好ましくはこれを欠失するように、操作されている、請求項20〜28のいずれか1つに記載の免疫原性組成物。
- 外膜小胞調製物の由来する宿主細胞が、msbBおよび/またはHtrB、好ましくはmsbBの発現をダウンレギュレートし、好ましくはこれを欠失するように、遺伝子操作されている、請求項20〜29のいずれか1つに記載の免疫原性組成物。
- 外膜小胞調製物が外膜タンパク質(OMP)とコンジュゲートしたLPSを含有する、請求項20〜30のいずれか1つに記載の免疫原性組成物。
- 外膜小胞調製物においてLPSがOMPとin situで(好ましくはブレブ内で)コンジュゲートしている、請求項31に記載の免疫原性組成物。
- 外膜小胞調製物の少なくとも一部がモラクセラ・カタラーリスに由来する、請求項20〜32のいずれか1つに記載の免疫原性組成物。
- 外膜小胞調製物の少なくとも一部がインフルエンザ菌に由来する、請求項20〜33のいずれか1つに記載の免疫原性組成物。
- グラム陰性細菌の2以上の菌株から分離された外膜小胞調製物を含んでなる、請求項20〜34のいずれか1つに記載の免疫原性組成物。
- トランスフェリン結合タンパク質およびHsf様タンパク質が、異なる細菌菌株を起源とする異なる小胞において、または同一菌株を起源とする同一小胞においてアップレギュレートされている、請求項35に記載の免疫原性組成物。
- 外膜小胞調製物においてトランスフェリン結合タンパク質発現の増大がグラム陰性細菌に導入された核酸から生じる、前記外膜小胞調製物を含んでなる請求項20〜36のいずれか1つに記載の免疫原性組成物。
- 外膜小胞調製物においてHsf様タンパク質発現の増大がグラム陰性細菌に導入された核酸から生じる、前記外膜小胞調製物を含んでなる請求項20〜37のいずれか1つに記載の免疫原性組成物。
- 外膜小胞調製物においてトランスフェリン結合タンパク質およびHsf様タンパク質発現の増大が、グラム陰性細菌に導入された、両方のタンパク質をコードする核酸から生じる、前記外膜小胞調製物を含んでなる請求項20〜38のいずれか1つに記載の免疫原性組成物。
- 細菌菌株が、トランスフェリン結合タンパク質をコードする遺伝子の上流により強力なプロモーター配列を導入するように遺伝子操作されている、請求項20〜39のいずれか1つに記載の免疫原性組成物。
- 細菌菌株が、Hsf様タンパク質をコードする遺伝子の上流により強力なプロモーター配列を導入するように遺伝子操作されている、請求項20〜40のいずれか1つに記載の免疫原性組成物。
- 細菌菌株が、トランスフェリン結合タンパク質およびHsf様タンパク質をコードする遺伝子の上流により強力なプロモーター配列を導入するように遺伝子操作されている、請求項20〜41のいずれか1つに記載の免疫原性組成物。
- トランスフェリン結合タンパク質はTbpAであるが、これは好ましくは高分子量TbpA、低分子量TbpA、または高分子量TbpAおよび低分子量TbpAの両方であって、もっとも好ましくは髄膜炎菌に由来する、請求項20〜42のいずれか1つに記載の免疫原性組成物。
- Hsf様タンパク質が髄膜炎菌に由来するHsfである、請求項20〜43のいずれか1つに記載の免疫原性組成物。
- コンジュゲートした、またはコンジュゲートしていない細菌莢膜多糖もしくはオリゴ糖をさらに含んでなる、請求項1〜44のいずれか1つに記載の免疫原性組成物。
- トランスフェリン結合タンパク質またはHsf様タンパク質またはその両方とコンジュゲートした2以上の細菌莢膜多糖もしくはオリゴ糖を含んでなる、請求項1〜45のいずれか1つに記載の免疫原性組成物。
- 莢膜多糖もしくはオリゴ糖が、髄膜炎菌血清群A、髄膜炎菌血清群C、髄膜炎菌血清群Y、髄膜炎菌血清群W-135、インフルエンザ菌b、肺炎連鎖球菌、A群連鎖球菌、B群連鎖球菌、黄色ブドウ球菌および表皮ブドウ球菌からなる群から選択される1以上の細菌に由来する、請求項45または46に記載の免疫原性組成物。
- トランスフェリン結合タンパク質またはその抗原性断片、およびHsf様タンパク質またはその抗原性断片をコードする1以上のポリヌクレオチドを含んでなり、その発現が真核生物プロモーターによって駆動される、免疫原性組成物。
- ナイセリア属細菌のTbpAおよびHsfがコードされる、請求項48に記載の免疫原性組成物。
- 髄膜炎菌のTbpAおよびHsfがコードされる、請求項48または49に記載の免疫原性組成物。
- アジュバントを含んでなる、請求項1〜50のいずれか1つに記載の免疫原性組成物。
- アルミニウム塩を含んでなる、請求項51に記載の免疫原性組成物。
- 3D-MPLを含んでなる、請求項51または52に記載の免疫原性組成物。
- CpGを含有するアジュバントを含んでなる、請求項51に記載の免疫原性組成物。
- 請求項1〜54のいずれか1つに記載の免疫原性組成物および製薬上許容される賦形剤を含んでなるワクチン。
- グラム陰性細菌感染を治療または予防するための薬剤の製造における、請求項55に記載のワクチンの使用。
- ナイセリア属細菌感染を治療または予防するための薬剤の製造における、請求項56に記載の使用。
- 請求項20〜44のいずれか1つに記載の免疫原性組成物に含まれる外膜小胞の起源とすることができる、遺伝子操作されたグラム陰性細菌菌株。
- 単離されたトランスフェリン結合タンパク質および単離されたHsf様タンパク質またはそれらの抗原性断片を混合するステップを含んでなる、請求項1〜17のいずれか1つに記載の免疫原性組成物を調製する方法。
- グラム陰性細菌培養物から外膜小胞を分離するステップを含んでなる、請求項20〜44のいずれか1つに記載の免疫原性組成物を作製する方法。
- 外膜小胞を分離するステップが、0〜0.5%、0.02〜0.4%、0.04〜0.3%、0.06〜0.2%、0.08〜0.15%または好ましくは0.1%の界面活性剤、好ましくはDOC、による抽出を含む、請求項60に記載の方法。
- 細菌莢膜多糖もしくはオリゴ糖をトランスフェリン結合タンパク質および/またはHsf様タンパク質とコンジュゲートするステップを含んでなる、請求項47に記載の免疫原性組成物を作製する方法。
- 請求項1〜54のいずれか1つに記載の免疫原性組成物を製薬上許容される賦形剤と混合するステップを含んでなる、請求項55に記載のワクチンを製造する方法。
- 請求項55に記載のワクチンを用いてレシピエントを免疫するステップ、および該レシピエントから免疫グロブリンを分離するステップを含んでなる、ナイセリア属細菌感染の予防または治療に使用するための免疫グロブリンを調製する方法。
- 請求項64に記載の方法から得られる、免疫グロブリン調製物。
- 請求項65に記載の免疫グロブリン調製物および製薬上許容される賦形剤を含んでなる、医薬品。
- 髄膜炎菌のTbpAおよびHsfに対するモノクローナル抗体、および製薬上許容される賦形剤を含んでなる、医薬品。
- グラム陰性細菌性疾患の治療または予防のための薬剤の製造における、請求項66または67に記載の医薬品の使用。
Applications Claiming Priority (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0218036.2 | 2002-08-02 | ||
GB0218035.4 | 2002-08-02 | ||
GB0218051A GB0218051D0 (en) | 2002-08-02 | 2002-08-02 | Vaccine composition |
GB0218051.1 | 2002-08-02 | ||
GB0218035A GB0218035D0 (en) | 2002-08-02 | 2002-08-02 | Vaccine composition |
GB0218037A GB0218037D0 (en) | 2002-08-02 | 2002-08-02 | Vaccine composition |
GB0218037.0 | 2002-08-02 | ||
GB0218036A GB0218036D0 (en) | 2002-08-02 | 2002-08-02 | Vaccine |
GB0220199.4 | 2002-08-30 | ||
GBGB0220199.4A GB0220199D0 (en) | 2002-08-30 | 2002-08-30 | Mutant protein and refolding method |
GBGB0220197.8A GB0220197D0 (en) | 2002-08-30 | 2002-08-30 | Refolding method |
GB0220197.8 | 2002-08-30 | ||
GB0225524.8 | 2002-11-01 | ||
GB0225531.3 | 2002-11-01 | ||
GB0225531A GB0225531D0 (en) | 2002-11-01 | 2002-11-01 | Vaccine |
GB0225524A GB0225524D0 (en) | 2002-11-01 | 2002-11-01 | Vaccine composition |
GB0230168A GB0230168D0 (en) | 2002-12-24 | 2002-12-24 | Vaccine composition |
GB0230164.6 | 2002-12-24 | ||
GB0230168.7 | 2002-12-24 | ||
GB0230170A GB0230170D0 (en) | 2002-12-24 | 2002-12-24 | Vaccine |
GB0230164A GB0230164D0 (en) | 2002-12-24 | 2002-12-24 | Vaccine composition |
GB0230170.3 | 2002-12-24 | ||
GB0305028A GB0305028D0 (en) | 2003-03-05 | 2003-03-05 | Vaccine |
GB0305028.3 | 2003-03-05 | ||
PCT/EP2003/008567 WO2004014419A1 (en) | 2002-08-02 | 2003-07-31 | Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006505628A JP2006505628A (ja) | 2006-02-16 |
JP2006505628A5 true JP2006505628A5 (ja) | 2006-09-14 |
JP5409986B2 JP5409986B2 (ja) | 2014-02-05 |
Family
ID=31722002
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005506112A Expired - Fee Related JP4740738B2 (ja) | 2002-08-02 | 2003-07-31 | ワクチン |
JP2005506113A Pending JP2006500963A (ja) | 2002-08-02 | 2003-07-31 | ワクチン組成物 |
JP2005506114A Pending JP2006506467A (ja) | 2002-08-02 | 2003-07-31 | ワクチン組成物 |
JP2005506111A Expired - Fee Related JP5409986B2 (ja) | 2002-08-02 | 2003-07-31 | グラム陰性細菌由来のトランスフェリン結合タンパク質およびHsfを含んでなるワクチン組成物 |
JP2010237357A Expired - Fee Related JP5414651B2 (ja) | 2002-08-02 | 2010-10-22 | ワクチン組成物 |
JP2011047056A Pending JP2011142916A (ja) | 2002-08-02 | 2011-03-04 | ワクチン |
JP2012026928A Expired - Fee Related JP5789203B2 (ja) | 2002-08-02 | 2012-02-10 | ワクチン組成物 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005506112A Expired - Fee Related JP4740738B2 (ja) | 2002-08-02 | 2003-07-31 | ワクチン |
JP2005506113A Pending JP2006500963A (ja) | 2002-08-02 | 2003-07-31 | ワクチン組成物 |
JP2005506114A Pending JP2006506467A (ja) | 2002-08-02 | 2003-07-31 | ワクチン組成物 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010237357A Expired - Fee Related JP5414651B2 (ja) | 2002-08-02 | 2010-10-22 | ワクチン組成物 |
JP2011047056A Pending JP2011142916A (ja) | 2002-08-02 | 2011-03-04 | ワクチン |
JP2012026928A Expired - Fee Related JP5789203B2 (ja) | 2002-08-02 | 2012-02-10 | ワクチン組成物 |
Country Status (26)
Country | Link |
---|---|
US (9) | US7838014B2 (ja) |
EP (11) | EP1524990A2 (ja) |
JP (7) | JP4740738B2 (ja) |
KR (6) | KR101239242B1 (ja) |
CN (2) | CN1674933B (ja) |
AU (6) | AU2003250204B8 (ja) |
CA (4) | CA2489030A1 (ja) |
CO (3) | CO5680455A2 (ja) |
CY (3) | CY1114243T1 (ja) |
DE (2) | DE20321889U1 (ja) |
DK (2) | DK1524993T3 (ja) |
ES (3) | ES2575014T3 (ja) |
HK (1) | HK1077014A1 (ja) |
HU (1) | HUE029200T2 (ja) |
IL (3) | IL165660A0 (ja) |
IS (3) | IS7593A (ja) |
LU (1) | LU92262I2 (ja) |
MX (3) | MXPA05001265A (ja) |
MY (1) | MY149591A (ja) |
NO (3) | NO20050008L (ja) |
NZ (4) | NZ587398A (ja) |
PL (5) | PL399492A1 (ja) |
PT (2) | PT1524993E (ja) |
SI (2) | SI1524993T1 (ja) |
TW (1) | TWI360424B (ja) |
WO (4) | WO2004014419A1 (ja) |
Families Citing this family (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2261343A3 (en) | 1998-05-01 | 2012-01-18 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
GB9823978D0 (en) * | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
US10967045B2 (en) * | 1998-11-02 | 2021-04-06 | Secretary of State for Health and Social Care | Multicomponent meningococcal vaccine |
DK1228217T3 (da) | 1999-04-30 | 2013-02-25 | Novartis Vaccines & Diagnostic | Konserverede neisseria-antigener |
CA2929348A1 (en) | 1999-05-19 | 2000-11-30 | Novartis Vaccines And Diagnostics S.R.L. | Combination neisserial compositions |
GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
ES2543736T3 (es) | 1999-10-29 | 2015-08-21 | Glaxosmithkline Biologicals Sa | Péptidos antigénicos de Neisseria |
GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
NZ520445A (en) * | 2000-01-25 | 2004-02-27 | Univ Queensland | Proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA |
PT2270030E (pt) * | 2000-02-28 | 2012-07-24 | Novartis Vaccines & Diagnostic | Expressão heteróloga de proteínas de neisseria |
KR20030024811A (ko) * | 2000-07-27 | 2003-03-26 | 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 | 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신 |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
EP2248822B1 (en) | 2001-07-27 | 2016-11-23 | GlaxoSmithKline Biologicals SA | Meningococcus adhesins |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
KR101239242B1 (ko) * | 2002-08-02 | 2013-03-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 항원 조합물을 포함하는 나이세리아 백신 조성물 |
GB0220194D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
AU2003274511B2 (en) * | 2002-10-11 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US8329192B2 (en) | 2003-09-19 | 2012-12-11 | Epitopix Llc | Campylobacter polypeptides and methods of use |
BRPI0415025A (pt) | 2003-10-02 | 2006-12-12 | Chiron Srl | vacinas lìquidas para sorogrupos meningocócicos múltiplos |
GB0323709D0 (en) * | 2003-10-09 | 2003-11-12 | Health Prot Agency | Modified whole cell,cell extract and omv-based vaccines |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
EP1706481A2 (en) | 2003-12-23 | 2006-10-04 | GlaxoSmithKline Biologicals S.A. | Vaccine |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
MXPA06013093A (es) * | 2004-05-11 | 2007-08-08 | Nederlanden Staat | Lipo-oligo-sacarido de neisseria meningitidis igtb como adyuvante. |
EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
GB0419408D0 (en) * | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
GB0419627D0 (en) * | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
DK2586456T3 (en) | 2004-10-29 | 2016-03-21 | Ratiopharm Gmbh | Conversion and glycopegylation of fibroblast growth factor (FGF) |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
GB0428381D0 (en) * | 2004-12-24 | 2005-02-02 | Isis Innovation | Vaccine |
ES2449195T3 (es) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Factor estimulante de colonias de granulocitos glicopegilado |
AU2006206234B2 (en) | 2005-01-21 | 2012-01-12 | Epitopix, Llc | Yersinia spp. polypeptides and methods of use |
CA2590974C (en) * | 2005-01-27 | 2017-10-03 | Children's Hospital & Research Center At Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US8329184B2 (en) | 2005-06-27 | 2012-12-11 | Glaxosmithkline Biologicals S.A. | Process for manufacturing vaccines |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US7955817B2 (en) | 2005-09-02 | 2011-06-07 | Glaxosmithkline Biologicals S.A. | Vaccine protection assay |
ATE485516T1 (de) | 2005-09-05 | 2010-11-15 | Glaxosmithkline Biolog Sa | Bakterizidie-serumtest für n. meningitidis spezifische antiseren |
WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
US20110008279A1 (en) * | 2005-12-06 | 2011-01-13 | Vega Masignani | Methods and Compositions Relating to Adhesins as Adjuvants |
PT1962899E (pt) | 2005-12-22 | 2011-10-19 | Glaxosmithkline Biolog Sa | Vacina conjugada polissacarídica pneumocócica |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
CU23549A1 (es) * | 2005-12-29 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Composiciones farmacéuticas que contienen la proteína nma0939 |
EA020459B1 (ru) | 2006-03-30 | 2014-11-28 | Глаксосмитклайн Байолоджикалс С.А. | Иммуногенная композиция |
DE602007003596D1 (de) * | 2006-06-12 | 2010-01-14 | Glaxosmithkline Biolog Sa | Impfstoff |
US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
EA016417B1 (ru) | 2006-09-07 | 2012-04-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ получения вакцины |
US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
GB0700136D0 (en) | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
WO2008124406A2 (en) | 2007-04-03 | 2008-10-16 | Neose Technologies, Inc. | Methods of treatment using glycopegylated g-csf |
EP2170919B8 (en) | 2007-06-12 | 2016-01-20 | ratiopharm GmbH | Improved process for the production of nucleotide sugars |
BRPI0813644B8 (pt) | 2007-06-26 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina |
EP2185576A4 (en) * | 2007-08-02 | 2011-01-12 | Childrens Hosp & Res Ct Oak | FHBP- AND LPXL1-BASED VESICIUM VACCINES FOR BROADBAND PROTECTION AGAINST NEISSERIA MENINGITIDIS-RELATED DISEASES |
BRPI0814793A2 (pt) * | 2007-08-02 | 2015-02-03 | Glaxosmithkline Biolog Sa | Método de tipagem molecular los de uma cepa neisseria, kit, e, método de diagnóstico e classificação de uma colonização de neisseria e/ou infecção em um hospedeiro susceptível à colonização de neisseria. |
SI2200642T1 (sl) | 2007-10-19 | 2012-06-29 | Novartis Ag | Formulacije meningokoknega cepiva |
US9579372B2 (en) | 2008-02-21 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Meningococcal fHBP polypeptides |
AU2009219232B2 (en) | 2008-02-27 | 2014-02-27 | Novo Nordisk A/S | Conjugated Factor VIII molecules |
CN102015651B (zh) | 2008-03-03 | 2014-12-31 | Irm责任有限公司 | 作为tlr活性调节剂的化合物和组合物 |
CA2726465A1 (en) * | 2008-05-30 | 2009-12-30 | Wendell David Zollinger | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
KR101042541B1 (ko) * | 2008-07-25 | 2011-06-17 | 한국생명공학연구원 | 외막소체를 생산하는 재조합 g(-) 박테리아 및 이를이용한 다가항원이 실린 외막소체의 제조방법 |
WO2010027729A2 (en) * | 2008-08-25 | 2010-03-11 | Creatv Microtech, Inc. | Gonococcal vaccines |
GB0816447D0 (en) * | 2008-09-08 | 2008-10-15 | Glaxosmithkline Biolog Sa | Vaccine |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
CN102300585A (zh) | 2008-12-17 | 2011-12-28 | 诺华有限公司 | 包含血红蛋白受体的脑膜炎球菌疫苗 |
CN102333539B (zh) | 2008-12-25 | 2014-06-25 | 一般财团法人化学及血清疗法研究所 | 重组禽传染性鼻炎疫苗及其制备方法 |
CN101759781B (zh) * | 2008-12-25 | 2013-04-03 | 上海市第六人民医院 | 一种细菌表层黏附蛋白及其用途 |
EP2208787A1 (en) * | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
PL2411048T3 (pl) | 2009-03-24 | 2020-11-16 | Glaxosmithkline Biologicals Sa | Adjuwantowe meningokokowe białko wiążące czynnik h |
JP5806204B2 (ja) * | 2009-03-24 | 2015-11-10 | ノバルティス アーゲー | 肺炎球菌血清型14の糖を含む組み合わせ |
WO2010109324A1 (en) | 2009-03-24 | 2010-09-30 | Novartis Ag | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
NZ597008A (en) * | 2009-05-14 | 2013-03-28 | Sanofi Pasteur | Meningococcal vaccine based on lipooligosaccharide (los) and neisseria meningitidis protein |
WO2010130896A2 (fr) | 2009-05-14 | 2010-11-18 | Sanofi Pasteur | Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif |
WO2010130898A2 (fr) | 2009-05-14 | 2010-11-18 | Sanofi Pasteur | Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6 |
WO2010134225A1 (ja) * | 2009-05-20 | 2010-11-25 | 国立大学法人鳥取大学 | 部分糖鎖エピトープを用いた、病原性ナイセリア属細菌感染の検出方法およびそれら細菌に対するワクチン |
CA2765112A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
NZ598458A (en) | 2009-08-27 | 2014-03-28 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
CN102740882A (zh) | 2009-08-27 | 2012-10-17 | 诺华有限公司 | 含有铝、寡核苷酸和聚阳离子的佐剂 |
EP2494865A4 (en) | 2009-09-01 | 2014-05-14 | Aeon Medix Inc | EXTRACELLULAR VESICLES OBTAINED FROM THE DARMFLORA, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE AND CANDIDATE AND DIAGNOSTIC METHOD THEREFOR |
WO2011027956A2 (ko) | 2009-09-04 | 2011-03-10 | 주식회사이언메딕스 | 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델 |
JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
MX2012002723A (es) | 2009-09-02 | 2012-04-11 | Novartis Ag | Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll. |
GB0917002D0 (en) * | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
CN102724988B (zh) | 2009-09-30 | 2014-09-10 | 诺华股份有限公司 | 脑膜炎球菌fHBP多肽的表达 |
JP5960055B2 (ja) | 2009-10-27 | 2016-08-02 | ノバルティス アーゲー | 改変髄膜炎菌fHBPポリペプチド |
WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
JP6166042B2 (ja) * | 2009-11-06 | 2017-07-19 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | T細胞刺激タンパク質bおよび使用方法 |
CN102762206A (zh) | 2009-12-15 | 2012-10-31 | 诺华有限公司 | 免疫增强化合物的均匀悬液及其用途 |
CA2792683A1 (en) | 2010-03-10 | 2011-09-15 | Glaxosmithkline Biologicals S.A. | Neisserial fhbp vaccine composition |
JP2013522177A (ja) * | 2010-03-11 | 2013-06-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | グラム陰性細菌性、例えば髄膜炎菌性の感染または疾患に対する免疫原性組成物またはワクチン |
WO2012020326A1 (en) | 2010-03-18 | 2012-02-16 | Novartis Ag | Adjuvanted vaccines for serogroup b meningococcus |
KR101853513B1 (ko) | 2010-03-23 | 2018-04-30 | 노파르티스 아게 | 감염, 염증, 호흡기 질환 등의 치료를 위해 사용되는 tlr2 효능제로서의 화합물 (시스테인 기재 리포펩티드) 및 조성물 |
CN107096025A (zh) * | 2010-03-29 | 2017-08-29 | 南加利福尼亚大学 | 用于去除生物膜的组合物及方法 |
AU2013202310C1 (en) * | 2010-03-29 | 2017-01-05 | Nationwide Children's Hospital, Inc. | Compositions and methods for the removal of biofilms |
EP2585106A1 (en) | 2010-06-25 | 2013-05-01 | Novartis AG | Combinations of meningococcal factor h binding proteins |
US20120128701A1 (en) | 2010-09-09 | 2012-05-24 | Nationwide Children's Hospital, Inc. | Compositions and methods for the removal of biofilms |
GB201015132D0 (en) | 2010-09-10 | 2010-10-27 | Univ Bristol | Vaccine composition |
ES2759484T3 (es) | 2010-09-10 | 2020-05-11 | Glaxosmithkline Biologicals Sa | Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo |
CN103228787B (zh) * | 2010-09-28 | 2017-06-23 | 阿贝拉生物科学公司 | 用于分泌性蛋白表达的融合蛋白 |
WO2012054879A1 (en) * | 2010-10-22 | 2012-04-26 | Duke University | Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia |
US20150147356A1 (en) | 2011-05-12 | 2015-05-28 | Alan Kimura | Antipyretics to enhance tolerability of vesicle-based vaccines |
JP6002763B2 (ja) | 2011-07-07 | 2016-10-05 | デ スタート デル ネダーランデン、フェルト.ドール デ ミニスター ファン フェーウェーエス | グラム陰性細菌の外膜小胞を、洗浄剤を含まずに生産するためのプロセス |
BR112014016223A8 (pt) | 2011-12-29 | 2017-07-04 | Novartis Ag | combinações adjuvantes de proteínas de ligação de fator h meningocócico |
WO2013113917A1 (en) | 2012-02-02 | 2013-08-08 | Novartis Ag | Promoters for increased protein expression in meningococcus |
JP5698693B2 (ja) * | 2012-03-13 | 2015-04-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 髄膜炎菌特異的抗血清に対する血清殺菌アッセイ |
WO2013186753A1 (en) | 2012-06-14 | 2013-12-19 | Novartis Ag | Vaccines for serogroup x meningococcus |
JP6324961B2 (ja) | 2012-09-06 | 2018-05-16 | ノバルティス アーゲー | 血清群b髄膜炎菌とd/t/pとの組み合わせワクチン |
US9764027B2 (en) | 2012-09-18 | 2017-09-19 | Glaxosmithkline Biologicals Sa | Outer membrane vesicles |
CA2900454A1 (en) | 2013-02-07 | 2014-08-14 | Glaxosmithkline Biologicals Sa | Pharmaceutical compositions comprising vesicles |
WO2014138290A1 (en) * | 2013-03-05 | 2014-09-12 | Trudeau Institute, Inc. | Compositions and methods for treating bacterial infections |
US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
US9745366B2 (en) | 2013-09-23 | 2017-08-29 | University Of Southern California | Compositions and methods for the prevention of microbial infections |
US10233234B2 (en) | 2014-01-13 | 2019-03-19 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
US11248040B2 (en) | 2013-09-26 | 2022-02-15 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
EP3782643A1 (en) | 2014-02-28 | 2021-02-24 | GlaxoSmithKline Biologicals SA | Modified meningococcal fhbp polypeptides |
US10232029B2 (en) | 2014-12-09 | 2019-03-19 | Sanofi Pasteur | Compositions comprising N. meningitidis proteins |
EP3838918B1 (en) | 2015-05-18 | 2022-08-31 | BiOMVis Srl | Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof |
WO2017023863A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
EP3365027B1 (en) | 2015-10-14 | 2022-03-30 | Research Institute at Nationwide Children's Hospital | Hu specific antibodies and their use in inhibiting biofilm |
KR101825439B1 (ko) * | 2016-04-15 | 2018-02-05 | 배재대학교 산학협력단 | 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법 |
EP3565589A1 (en) | 2017-01-04 | 2019-11-13 | Research Institute at Nationwide Children's Hospital | Dnabii vaccines and antibodies with enhanced activity |
WO2018170178A1 (en) | 2017-03-15 | 2018-09-20 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
EP3607967A1 (en) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
AU2019376832B2 (en) * | 2018-11-06 | 2024-01-25 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
US20220125908A1 (en) * | 2019-02-14 | 2022-04-28 | University Of Florida Research Foundation, Incorporated | Honeybee commensal snodgrassella alvi vaccine against pathogenic neisseriaceae |
FR3099160B1 (fr) * | 2019-07-23 | 2022-05-06 | Univ Grenoble Alpes | Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant |
WO2023097652A1 (en) * | 2021-12-03 | 2023-06-08 | National Center For Nanoscience And Technology | An engineered cell and application thereof |
GB202203250D0 (en) | 2022-03-09 | 2022-04-20 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4239746A (en) * | 1973-06-30 | 1980-12-16 | Dezso Istvan Bartos | Complement fixation test employing reactants in a disposable package |
DE2744721A1 (de) | 1977-10-05 | 1979-04-19 | Veba Chemie Ag | Pulverfoermige ueberzugsmittel und deren anwendung |
DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
EP0027888B1 (en) | 1979-09-21 | 1986-04-16 | Hitachi, Ltd. | Semiconductor switch |
US4271147A (en) | 1980-01-10 | 1981-06-02 | Behringwerke Aktiengesellschaft | Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US20020146764A1 (en) * | 1985-03-28 | 2002-10-10 | Chiron Corporation | Expression using fused genes providing for protein product |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
DE3622221A1 (de) * | 1986-07-02 | 1988-01-14 | Max Planck Gesellschaft | Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen |
US5173294A (en) | 1986-11-18 | 1992-12-22 | Research Foundation Of State University Of New York | Dna probe for the identification of haemophilus influenzae |
RU2023448C1 (ru) | 1987-07-30 | 1994-11-30 | Сентро Насьональ Де Биопрепарадос | Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в |
DE68929323T2 (de) | 1988-12-16 | 2002-04-18 | Nederlanden Staat | Pneumolysin-mutanten und pneumokokken-impfstoffe daraus |
US7118757B1 (en) * | 1988-12-19 | 2006-10-10 | Wyeth Holdings Corporation | Meningococcal class 1 outer-membrane protein vaccine |
CU22302A1 (es) * | 1990-09-07 | 1995-01-31 | Cigb | Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales |
ATE242784T1 (de) | 1990-07-16 | 2003-06-15 | Univ North Carolina | Mit der familie der hämolysin-toxine verwandte antigene eisen-ubnterdrückende proteine des n. meningitis |
DE4023721A1 (de) | 1990-07-26 | 1992-01-30 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von vakzinen und ihre verwendung |
US5912336A (en) | 1990-08-23 | 1999-06-15 | University Of North Carolina At Chapel Hill | Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis |
ES2329979T3 (es) | 1990-08-23 | 2009-12-03 | The University Of North Carolina At Chapel Hill | Proteinas de union de transferencia de neisseria gonorrhoeae y neisseria meningitis. su uso como vacuna. |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
US5371186A (en) | 1991-02-11 | 1994-12-06 | Biosynth S.R.L. | Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock |
US5652211A (en) | 1991-02-11 | 1997-07-29 | Biosynth S.R.L. | Peptides for neutralizing the toxicity of Lipid A |
US6592876B1 (en) | 1993-04-20 | 2003-07-15 | Uab Research Foundation | Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products |
US5476929A (en) | 1991-02-15 | 1995-12-19 | Uab Research Foundation | Structural gene of pneumococcal protein |
ES2127217T3 (es) * | 1991-03-14 | 1999-04-16 | Imclone Systems Inc | Epitopos de porina hibridos de recombinacion. |
US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
FR2682041B1 (fr) | 1991-10-03 | 1994-01-14 | Pasteur Merieux Serums Vaccins | Vaccin contre les infections a neisseria meningitidis. |
CA2127871A1 (en) | 1992-01-13 | 1993-07-22 | Andreas Herman Hogt | Crosslinking of rubbers with engineering plastics |
DE69333107T2 (de) | 1992-02-11 | 2004-01-29 | Jackson H M Found Military Med | Dualer träger für immunogene konstrukte |
FR2692592B1 (fr) | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
PL170980B1 (pl) | 1992-06-25 | 1997-02-28 | Smithkline Beecham Biolog | Szczepionka PL PL PL PL PL PL PL |
NL9201716A (nl) | 1992-10-02 | 1994-05-02 | Nederlanden Staat | Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat. |
GB9224584D0 (en) | 1992-11-23 | 1993-01-13 | Connaught Lab | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases |
ATE226831T1 (de) | 1993-05-18 | 2002-11-15 | Univ Ohio State Res Found | Impfstoff gegen mittelohrentzündung |
US5439808A (en) * | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
CN1990503A (zh) | 1993-11-08 | 2007-07-04 | 康诺特实验室有限公司 | 嗜血杆菌属转铁蛋白受体基因 |
US6361779B1 (en) | 1993-11-08 | 2002-03-26 | Aventis Pasteur Limited | Transferrin receptor genes |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
US5565204A (en) | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
US5545553A (en) | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
US6287574B1 (en) * | 1995-03-17 | 2001-09-11 | Biochem Pharma Inc. | Proteinase K resistant surface protein of neisseria meningitidis |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
US6265567B1 (en) | 1995-04-07 | 2001-07-24 | University Of North Carolina At Chapel Hill | Isolated FrpB nucleic acid molecule |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
US6007838A (en) | 1995-06-07 | 1999-12-28 | The United States Of America As Represented By The Secretary Of The Army | Process for making liposome preparation |
BR9609399A (pt) | 1995-06-07 | 2001-08-28 | Biochem Vaccines Inc | Elementos de proteìnas de choque térmico estreptocócicos da famìlia hsp70 |
GB9513074D0 (en) | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
ES2217325T5 (es) * | 1995-09-18 | 2009-04-01 | United States Army Medical Research Materiel Command (Usamrmc) | Metodos mejorados para la produccion de vacunas de subunidades multivalentes de proteosomas acomplejados no covalentemente. |
US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
US6440701B1 (en) | 1996-03-08 | 2002-08-27 | Aventis Pasteur Limited | Transferrin receptor genes of Moraxella |
US6090576A (en) | 1996-03-08 | 2000-07-18 | Connaught Laboratories Limited | DNA encoding a transferrin receptor of Moraxella |
CA2253252A1 (en) | 1996-05-01 | 1997-11-06 | The Rockefeller University | Choline binding proteins for anti-pneumococcal vaccines |
US7341727B1 (en) | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
FR2751000B1 (fr) * | 1996-07-12 | 1998-10-30 | Inst Nat Sante Rech Med | Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques |
US5882871A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | Saliva binding protein |
US5882896A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | M protein |
EP1770164B1 (en) | 1996-10-31 | 2010-09-01 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
CA2292838A1 (en) | 1997-06-03 | 1998-12-10 | Connaught Laboratories Limited | Lactoferrin receptor genes of moraxella |
EP0998557A2 (en) | 1997-07-21 | 2000-05-10 | North American Vaccine, Inc. | Modified immunogenic pneumolysin, compositions and their use as vaccines |
WO1999006781A1 (de) | 1997-07-31 | 1999-02-11 | Wilo Gmbh | Latentwärmespeicher für ein kraftfahrzeug |
CN1204253C (zh) | 1997-08-15 | 2005-06-01 | 乌得勒支大学 | 奈瑟氏球菌乳铁蛋白结合蛋白 |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
US6914131B1 (en) * | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
GB9726398D0 (en) * | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
CA2317815A1 (en) * | 1998-01-14 | 1999-07-22 | Chiron S.P.A. | Neisseria meningitidis antigens |
CA2264970A1 (en) * | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria |
CN1200731C (zh) | 1998-04-07 | 2005-05-11 | 免疫医疗公司 | 用作疫苗的肺炎球菌胆碱结合蛋白衍生物 |
GB9808734D0 (en) | 1998-04-23 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
EP2261343A3 (en) * | 1998-05-01 | 2012-01-18 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
US20070026021A1 (en) * | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
GB9809683D0 (en) | 1998-05-06 | 1998-07-01 | Smithkline Beecham Biolog | Novel compounds |
GB9810285D0 (en) | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
GB9810276D0 (en) | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
GB9811260D0 (en) | 1998-05-26 | 1998-07-22 | Smithkline Beecham Biolog | Novel compounds |
US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
US6803043B1 (en) | 1998-06-03 | 2004-10-12 | Glaxosmithkline Biologicals S.A. | Basbo27 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses |
GB9812163D0 (en) | 1998-06-05 | 1998-08-05 | Smithkline Beecham Biolog | Novel compounds |
GB9812440D0 (en) | 1998-06-09 | 1998-08-05 | Smithkline Beecham Biolog | Novel compounds |
GB9814902D0 (en) | 1998-07-10 | 1998-09-09 | Univ Nottingham | Screening of neisserial vaccine candidates against pathogenic neisseria |
US6951652B2 (en) | 1998-07-29 | 2005-10-04 | Biosynth S.R.L. | Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases |
GB9818004D0 (en) * | 1998-08-18 | 1998-10-14 | Smithkline Beecham Biolog | Novel compounds |
GB9820003D0 (en) | 1998-09-14 | 1998-11-04 | Smithkline Beecham Biolog | Novel compounds |
GB9820002D0 (en) | 1998-09-14 | 1998-11-04 | Smithkline Beecham Biolog | Novel compounds |
JP2004511201A (ja) * | 1998-10-09 | 2004-04-15 | カイロン コーポレイション | ナイセリアゲノム配列およびそれらの使用方法 |
CA2345903C (en) | 1998-10-16 | 2006-09-26 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Molecular pathogenicide mediated plant disease resistance |
US6610306B2 (en) * | 1998-10-22 | 2003-08-26 | The University Of Montana | OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof |
EP1123403A1 (en) * | 1998-10-22 | 2001-08-16 | The University Of Montana | OMP85 PROTEINS OF $i(NEISSERIA GONORRHOEAE) AND $i(NEISSERIA MENINGITIDIS), COMPOSITIONS CONTAINING SAME AND METHODS OF USE THEREOF |
GB9823978D0 (en) * | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
US20030215469A1 (en) * | 1998-11-02 | 2003-11-20 | Microbiological Research Authority | Multicomponent meningococcal vaccine |
ATE373714T1 (de) | 1998-11-03 | 2007-10-15 | Nederlanden Staat | Lps mit reduzierter toxizität von genetisch modifizierten gram-negativen bakterien |
CA2371032A1 (en) * | 1999-04-30 | 2000-11-09 | Chiron Corporation | Neisseria genomic sequences and methods of their use |
DK1228217T3 (da) * | 1999-04-30 | 2013-02-25 | Novartis Vaccines & Diagnostic | Konserverede neisseria-antigener |
GB9911683D0 (en) * | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
CA2929348A1 (en) | 1999-05-19 | 2000-11-30 | Novartis Vaccines And Diagnostics S.R.L. | Combination neisserial compositions |
CA2378687A1 (en) | 1999-06-18 | 2000-12-28 | Elitra Pharmaceuticals, Inc. | Nucleotide sequences of moraxella catarrhalis genome |
GB2351515B (en) | 1999-06-29 | 2002-09-11 | Pandrol Ltd | Adjustable railway rail fastening assembly and methods for use therewith |
GB9917977D0 (en) | 1999-07-30 | 1999-09-29 | Smithkline Beecham Biolog | Novel compounds |
GB9918038D0 (en) | 1999-07-30 | 1999-09-29 | Smithkline Beecham Biolog | Novel compounds |
GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
GB9918208D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Novel compounds |
GB9918302D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Novel compounds |
US6531131B1 (en) | 1999-08-10 | 2003-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for Neisseria meningitidis |
AUPQ275799A0 (en) * | 1999-09-10 | 1999-10-07 | Luminis Pty Limited | Recombinant bacterium expressing an oligosaccharide receptor mimic |
EP1234039A2 (en) | 1999-11-29 | 2002-08-28 | Chiron Spa | 85kDa NEISSERIAL ANTIGEN |
DK2289545T3 (en) | 2000-01-17 | 2016-09-05 | Glaxosmithkline Biologicals Sa | Supplemented OMV vaccine against meningococcus |
NZ520445A (en) * | 2000-01-25 | 2004-02-27 | Univ Queensland | Proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA |
PT2270030E (pt) * | 2000-02-28 | 2012-07-24 | Novartis Vaccines & Diagnostic | Expressão heteróloga de proteínas de neisseria |
GB0007432D0 (en) * | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
GB0011108D0 (en) * | 2000-05-08 | 2000-06-28 | Microscience Ltd | Virulence gene and protein and their use |
KR20030024811A (ko) | 2000-07-27 | 2003-03-26 | 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 | 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신 |
GB0103424D0 (en) * | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
GB0108024D0 (en) * | 2001-03-30 | 2001-05-23 | Chiron Spa | Bacterial toxins |
GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
WO2003009869A1 (en) | 2001-07-26 | 2003-02-06 | Chiron Srl. | Vaccines comprising aluminium adjuvants and histidine |
GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
EP2248822B1 (en) * | 2001-07-27 | 2016-11-23 | GlaxoSmithKline Biologicals SA | Meningococcus adhesins |
NZ532274A (en) | 2001-10-03 | 2006-02-24 | Chiron Corp | Adjuvanted meningococcus compositions |
KR101239242B1 (ko) * | 2002-08-02 | 2013-03-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 항원 조합물을 포함하는 나이세리아 백신 조성물 |
AU2003274511B2 (en) * | 2002-10-11 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
CN102302776B (zh) * | 2003-01-30 | 2014-06-18 | 诺华疫苗和诊断有限公司 | 抗多种脑膜炎球菌血清组的可注射性疫苗 |
GB0315021D0 (en) * | 2003-06-26 | 2003-07-30 | Chiron Srl | Immunogenic gonococcal compositions |
BRPI0415025A (pt) * | 2003-10-02 | 2006-12-12 | Chiron Srl | vacinas lìquidas para sorogrupos meningocócicos múltiplos |
GB0323103D0 (en) * | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
GB0408977D0 (en) * | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0409748D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Lactoferrin cleavage |
WO2008001224A2 (en) * | 2006-06-29 | 2008-01-03 | Novartis Ag | Polypeptides from neisseria meningitidis |
-
2003
- 2003-07-31 KR KR1020127002482A patent/KR101239242B1/ko not_active IP Right Cessation
- 2003-07-31 KR KR1020057001924A patent/KR20050028051A/ko not_active Application Discontinuation
- 2003-07-31 EP EP03750408A patent/EP1524990A2/en not_active Withdrawn
- 2003-07-31 PL PL399492A patent/PL399492A1/pl not_active Application Discontinuation
- 2003-07-31 EP EP10177881A patent/EP2258384A3/en not_active Withdrawn
- 2003-07-31 AU AU2003250204A patent/AU2003250204B8/en not_active Ceased
- 2003-07-31 NZ NZ587398A patent/NZ587398A/en not_active IP Right Cessation
- 2003-07-31 US US10/523,044 patent/US7838014B2/en not_active Expired - Fee Related
- 2003-07-31 PL PL375407A patent/PL216662B1/pl unknown
- 2003-07-31 CA CA002489030A patent/CA2489030A1/en not_active Abandoned
- 2003-07-31 US US10/523,114 patent/US20060034854A1/en not_active Abandoned
- 2003-07-31 WO PCT/EP2003/008567 patent/WO2004014419A1/en active Application Filing
- 2003-07-31 DK DK03784153.3T patent/DK1524993T3/da active
- 2003-07-31 EP EP12157807.4A patent/EP2481419A3/en not_active Withdrawn
- 2003-07-31 JP JP2005506112A patent/JP4740738B2/ja not_active Expired - Fee Related
- 2003-07-31 PL PL03375408A patent/PL375408A1/xx not_active Application Discontinuation
- 2003-07-31 DK DK10177890.0T patent/DK2255826T3/en active
- 2003-07-31 SI SI200332262T patent/SI1524993T1/sl unknown
- 2003-07-31 EP EP10177891A patent/EP2258386A3/en not_active Withdrawn
- 2003-07-31 NZ NZ574530A patent/NZ574530A/en not_active IP Right Cessation
- 2003-07-31 US US10/523,055 patent/US20060057160A1/en not_active Abandoned
- 2003-07-31 MY MYPI20032904A patent/MY149591A/en unknown
- 2003-07-31 MX MXPA05001265A patent/MXPA05001265A/es active IP Right Grant
- 2003-07-31 PL PL03375382A patent/PL375382A1/xx not_active IP Right Cessation
- 2003-07-31 EP EP03784151A patent/EP1524991A1/en not_active Withdrawn
- 2003-07-31 EP EP10177890.0A patent/EP2255826B1/en not_active Expired - Lifetime
- 2003-07-31 EP EP10177892A patent/EP2258387A3/en not_active Withdrawn
- 2003-07-31 EP EP08153843A patent/EP1961427A3/en not_active Withdrawn
- 2003-07-31 NZ NZ537181A patent/NZ537181A/en not_active IP Right Cessation
- 2003-07-31 PT PT37841533T patent/PT1524993E/pt unknown
- 2003-07-31 KR KR1020117004904A patent/KR101237329B1/ko not_active IP Right Cessation
- 2003-07-31 DE DE20321889U patent/DE20321889U1/de not_active Expired - Lifetime
- 2003-07-31 WO PCT/EP2003/008571 patent/WO2004014418A2/en active Application Filing
- 2003-07-31 EP EP03784153A patent/EP1524993B1/en not_active Revoked
- 2003-07-31 SI SI200332485A patent/SI2255826T1/sl unknown
- 2003-07-31 AU AU2003253375A patent/AU2003253375B2/en not_active Ceased
- 2003-07-31 CN CN038186489A patent/CN1674933B/zh not_active Expired - Fee Related
- 2003-07-31 CN CNA038184540A patent/CN1671413A/zh active Pending
- 2003-07-31 ES ES10177890.0T patent/ES2575014T3/es not_active Expired - Lifetime
- 2003-07-31 HU HUE10177890A patent/HUE029200T2/en unknown
- 2003-07-31 AU AU2003260357A patent/AU2003260357B2/en not_active Ceased
- 2003-07-31 CA CA002493092A patent/CA2493092A1/en not_active Abandoned
- 2003-07-31 KR KR1020057001941A patent/KR101140033B1/ko not_active IP Right Cessation
- 2003-07-31 JP JP2005506113A patent/JP2006500963A/ja active Pending
- 2003-07-31 US US10/523,117 patent/US20060240045A1/en not_active Abandoned
- 2003-07-31 KR KR1020057001933A patent/KR20050039839A/ko not_active Application Discontinuation
- 2003-07-31 EP EP03784152.5A patent/EP1524992B1/en not_active Expired - Lifetime
- 2003-07-31 CA CA2493124A patent/CA2493124C/en not_active Expired - Fee Related
- 2003-07-31 AU AU2003269864A patent/AU2003269864A1/en not_active Abandoned
- 2003-07-31 JP JP2005506114A patent/JP2006506467A/ja active Pending
- 2003-07-31 PL PL399214A patent/PL220107B1/pl unknown
- 2003-07-31 JP JP2005506111A patent/JP5409986B2/ja not_active Expired - Fee Related
- 2003-07-31 WO PCT/EP2003/008568 patent/WO2004014417A2/en active Application Filing
- 2003-07-31 PT PT101778900T patent/PT2255826E/pt unknown
- 2003-07-31 DE DE20321890U patent/DE20321890U1/de not_active Expired - Lifetime
- 2003-07-31 ES ES03784152.5T patent/ES2537737T3/es not_active Expired - Lifetime
- 2003-07-31 EP EP10177887A patent/EP2258385A3/en not_active Withdrawn
- 2003-07-31 NZ NZ537904A patent/NZ537904A/en not_active IP Right Cessation
- 2003-07-31 WO PCT/EP2003/008569 patent/WO2004015099A2/en active Application Filing
- 2003-07-31 TW TW092121011A patent/TWI360424B/zh not_active IP Right Cessation
- 2003-07-31 KR KR1020087019883A patent/KR101139976B1/ko not_active IP Right Cessation
- 2003-07-31 MX MXPA05001349A patent/MXPA05001349A/es active IP Right Grant
- 2003-07-31 ES ES03784153T patent/ES2408251T3/es not_active Expired - Lifetime
- 2003-07-31 MX MXPA05000842A patent/MXPA05000842A/es active IP Right Grant
- 2003-07-31 CA CA002493977A patent/CA2493977A1/en not_active Abandoned
-
2004
- 2004-12-09 IL IL16566004A patent/IL165660A0/xx unknown
- 2004-12-13 IS IS7593A patent/IS7593A/is unknown
- 2004-12-16 IS IS7601A patent/IS7601A/is unknown
-
2005
- 2005-01-03 NO NO20050008A patent/NO20050008L/no not_active Application Discontinuation
- 2005-01-03 NO NO20050010A patent/NO20050010L/no not_active Application Discontinuation
- 2005-01-20 IS IS7658A patent/IS7658A/is unknown
- 2005-01-20 IL IL166433A patent/IL166433A/en active IP Right Grant
- 2005-01-25 NO NO20050421A patent/NO20050421L/no not_active Application Discontinuation
- 2005-01-28 CO CO05007266A patent/CO5680455A2/es not_active Application Discontinuation
- 2005-01-28 CO CO05007268A patent/CO5680456A2/es not_active Application Discontinuation
- 2005-01-28 CO CO05007265A patent/CO5680454A2/es active IP Right Grant
- 2005-10-13 HK HK05109073.6A patent/HK1077014A1/xx not_active IP Right Cessation
-
2008
- 2008-06-04 AU AU2008202479A patent/AU2008202479C1/en not_active Ceased
- 2008-12-12 AU AU2008255270A patent/AU2008255270A1/en not_active Abandoned
-
2010
- 2010-10-21 US US12/909,621 patent/US8221770B2/en not_active Expired - Fee Related
- 2010-10-22 JP JP2010237357A patent/JP5414651B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-04 JP JP2011047056A patent/JP2011142916A/ja active Pending
- 2011-05-31 IL IL213264A patent/IL213264A0/en unknown
- 2011-09-29 US US13/248,693 patent/US20120027800A1/en not_active Abandoned
- 2011-11-17 US US13/299,007 patent/US20120064119A1/en not_active Abandoned
- 2011-11-17 US US13/299,041 patent/US20120064120A1/en not_active Abandoned
-
2012
- 2012-02-10 JP JP2012026928A patent/JP5789203B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-31 CY CY20131100435T patent/CY1114243T1/el unknown
- 2013-07-31 LU LU92262C patent/LU92262I2/fr unknown
- 2013-09-05 CY CY2013036C patent/CY2013036I2/el unknown
-
2015
- 2015-09-03 US US14/844,989 patent/US20160082097A1/en not_active Abandoned
-
2016
- 2016-06-15 CY CY20161100532T patent/CY1117643T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006505628A5 (ja) | ||
JP2006506467A5 (ja) | ||
RU2325184C2 (ru) | Улучшенные везикулы наружной мембраны бактерий | |
JP4740738B2 (ja) | ワクチン | |
JP5275983B2 (ja) | ワクチン | |
RU2607021C2 (ru) | Способ бездетергентного получения везикул наружной мембраны грамотрицательной бактерии | |
JP2016135139A (ja) | 外膜タンパク質を有する免疫原性細菌小胞 | |
CN103002910A (zh) | 疫苗组合物 | |
JPH03501123A (ja) | グラム陰性非腸内病原性桿菌に対する獣医学用の無細胞ワクチンの調製方法 | |
RU2005102587A (ru) | Вакцинная композиция, содержащая трансферрин-связывающий белок и hsf из грамотрицательных бактерий | |
CN102552895B (zh) | 疫苗组合物 |